SK Biopharmaceuticals Co Ltd
KRX:326030
SK Biopharmaceuticals Co Ltd
KRX:326030
Price:
95 400
KRW
-2.25%
Market Closed
Market Cap:
7.5T
KRW
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
Do you really want to delete this note?
This action cannot be undone.
Alert
SK Biopharmaceuticals Co Ltd
95400
-2200 (-2.25%)
| 52 Week Range |
75 700
125 900
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
Delete Alert
This alert will be permanently deleted.
Ask me anything about
SK Biopharmaceuticals Co Ltd
Cash Flow Statement
Cash Flow Statement
SK Biopharmaceuticals Co Ltd
SK Biopharmaceuticals Co Ltd
Currency: KRW
| Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | |||||||||||||||||||||
| Net Income |
(71 519)
|
(210 214)
|
(229 536)
|
(242 366)
|
(247 414)
|
(51 828)
|
(59 196)
|
(40 396)
|
64 846
|
(99 351)
|
(77 756)
|
(48 445)
|
(139 431)
|
(106 594)
|
(84 533)
|
(87 985)
|
(35 379)
|
(23 313)
|
24 588
|
49 310
|
|
| Depreciation & Amortization |
6 501
|
7 140
|
7 859
|
9 488
|
10 859
|
11 646
|
12 168
|
11 844
|
11 642
|
11 870
|
12 160
|
12 568
|
12 984
|
13 301
|
13 604
|
14 222
|
15 317
|
16 309
|
17 132
|
17 459
|
|
| Other Non-Cash Items |
(9 214)
|
(8 851)
|
(6 707)
|
(8 898)
|
15 110
|
13 795
|
23 517
|
13 478
|
(95 838)
|
(94 173)
|
(101 543)
|
(86 481)
|
35 848
|
13 734
|
9 173
|
12 193
|
5 643
|
27 853
|
39 624
|
39 161
|
|
| Cash Taxes Paid |
708
|
722
|
432
|
317
|
6 389
|
6 548
|
7 840
|
11 946
|
6 160
|
9 191
|
6 369
|
4 118
|
4 681
|
1 804
|
7 735
|
7 206
|
8 126
|
8 203
|
10 475
|
12 604
|
|
| Cash Interest Paid |
1 234
|
2 165
|
4 131
|
4 540
|
4 441
|
3 710
|
1 838
|
1 225
|
844
|
832
|
1 012
|
2 053
|
3 488
|
5 006
|
6 436
|
7 423
|
8 142
|
8 458
|
9 297
|
9 528
|
|
| Change in Working Capital |
(6 694)
|
5 841
|
(19 015)
|
(28 111)
|
7 465
|
(158 645)
|
(139 940)
|
(18 762)
|
(73 521)
|
68 180
|
70 946
|
(66 636)
|
(69 321)
|
(71 901)
|
(79 706)
|
(58 330)
|
(79 782)
|
(48 092)
|
(88 093)
|
(86 191)
|
|
| Cash from Operating Activities |
(80 926)
N/A
|
(206 085)
-155%
|
(247 399)
-20%
|
(269 888)
-9%
|
(213 980)
+21%
|
(185 031)
+14%
|
(163 450)
+12%
|
(33 834)
+79%
|
(92 872)
-174%
|
(113 474)
-22%
|
(96 193)
+15%
|
(188 994)
-96%
|
(159 920)
+15%
|
(151 460)
+5%
|
(141 462)
+7%
|
(119 901)
+15%
|
(94 201)
+21%
|
(27 243)
+71%
|
(6 749)
+75%
|
19 738
N/A
|
|
| Investing Cash Flow | |||||||||||||||||||||
| Capital Expenditures |
(14 048)
|
(13 869)
|
(12 966)
|
(14 025)
|
(14 336)
|
(15 232)
|
(12 117)
|
(8 359)
|
(5 992)
|
(5 299)
|
(6 162)
|
(5 825)
|
(5 961)
|
(6 206)
|
(5 084)
|
(4 648)
|
(3 249)
|
(2 700)
|
(2 241)
|
(13 719)
|
|
| Other Items |
(25 417)
|
38 726
|
(59 159)
|
(272 211)
|
(304 394)
|
(168 931)
|
(69 960)
|
199 280
|
264 963
|
63 697
|
41 863
|
(95 417)
|
(89 753)
|
2 998
|
59 942
|
284 420
|
228 522
|
182 243
|
149 954
|
2 739
|
|
| Cash from Investing Activities |
(39 465)
N/A
|
24 857
N/A
|
(72 126)
N/A
|
(286 235)
-297%
|
(318 730)
-11%
|
(184 163)
+42%
|
(82 077)
+55%
|
190 920
N/A
|
258 971
+36%
|
58 397
-77%
|
35 701
-39%
|
(101 242)
N/A
|
(95 714)
+5%
|
(3 208)
+97%
|
54 857
N/A
|
279 772
+410%
|
225 273
-19%
|
179 542
-20%
|
147 713
-18%
|
(10 979)
N/A
|
|
| Financing Cash Flow | |||||||||||||||||||||
| Net Issuance of Common Stock |
0
|
0
|
645 465
|
645 465
|
645 465
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Net Issuance of Debt |
97 241
|
196 878
|
196 114
|
(54 529)
|
(104 562)
|
(204 901)
|
(204 618)
|
(54 705)
|
(4 827)
|
36 818
|
36 679
|
136 522
|
136 274
|
94 449
|
94 366
|
(5 558)
|
(5 575)
|
19 453
|
19 806
|
(4 884)
|
|
| Other |
0
|
0
|
0
|
0
|
0
|
6
|
(6)
|
86
|
181
|
(464)
|
(439)
|
(529)
|
(1 360)
|
0
|
(684)
|
19 833
|
12 198
|
0
|
12 147
|
(8 372)
|
|
| Cash from Financing Activities |
97 241
N/A
|
196 878
+102%
|
841 579
+327%
|
590 936
-30%
|
540 902
-8%
|
440 569
-19%
|
(204 624)
N/A
|
(54 619)
+73%
|
(4 646)
+91%
|
36 354
N/A
|
36 240
0%
|
135 993
+275%
|
134 914
-1%
|
93 729
-31%
|
93 683
0%
|
14 275
-85%
|
6 623
-54%
|
31 651
+378%
|
31 953
+1%
|
(13 256)
N/A
|
|
| Change in Cash | |||||||||||||||||||||
| Effect of Foreign Exchange Rates |
0
|
732
|
1 706
|
(68)
|
0
|
2 054
|
1 144
|
4 721
|
5 135
|
5 287
|
10 065
|
16 503
|
(1 143)
|
(6 663)
|
(13 487)
|
(18 199)
|
(2 054)
|
1 980
|
5 503
|
(865)
|
|
| Net Change in Cash |
(23 150)
N/A
|
16 382
N/A
|
523 760
+3 097%
|
34 745
-93%
|
8 192
-76%
|
73 429
+796%
|
(449 007)
N/A
|
107 188
N/A
|
166 589
+55%
|
(13 436)
N/A
|
(14 187)
-6%
|
(137 739)
-871%
|
(121 863)
+12%
|
(67 602)
+45%
|
(6 409)
+91%
|
155 947
N/A
|
135 640
-13%
|
185 931
+37%
|
178 419
-4%
|
(5 361)
N/A
|
|
| Free Cash Flow | |||||||||||||||||||||
| Free Cash Flow |
(94 974)
N/A
|
(219 954)
-132%
|
(260 365)
-18%
|
(283 913)
-9%
|
(228 317)
+20%
|
(200 263)
+12%
|
(175 567)
+12%
|
(42 193)
+76%
|
(98 864)
-134%
|
(118 773)
-20%
|
(102 355)
+14%
|
(194 819)
-90%
|
(165 881)
+15%
|
(157 666)
+5%
|
(146 546)
+7%
|
(124 549)
+15%
|
(97 451)
+22%
|
(29 943)
+69%
|
(8 990)
+70%
|
6 020
N/A
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
